- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis Access for Pain Treatment Medical Cannabis in America
- Join Join
In 1988, DEA Administrative Law Judge Francis Young ruled that, “Marijuana, in its natural form, is one of the safest therapeutically active substances known to man.” And, although the DEA ignored Judge Young’s recommendation to reclassify the plant from its federal status as a dangerous drug with no medical value, smoking cannabis remains relatively benign with little-to-no side effects.
That said, it’s important to understand certain safety consequences with regard to cultivating cannabis, especially in light of its increased commercialization in medical marijuana states. As an example, in May the States of California and Oregon removed from the retail hydroponic market several popular flowering additives after the California Department of Food and Agriculture (CDFA) found them to contain high levels of long-banned Daminozide (Alar), a known “probable” human carcinogen.
A subsequent Freedom of Information Act request yielded the concentrations of Daminozide in products such as Flower Dragon, Phosphoload, and Top Load. Two other products quarantined in the CDFA sweep, Emerald Triangle Bushmaster and Gravity, were found to contain Paclobutrazol, which has been listed by the World Health Organization (WHO) as moderately hazardous and banned for use in many European countries.
According to G. Low, author of Integral Hydroponics and the one who filed the recent FOIA request, “In field situations, Paclobutrazol has a half-life ranging from 3 to12 months, but could persist as long as 3 years.” G. Low added that:
Both Paclobutrazol and Daminozide are systemic products with long withholding periods, meaning that it is likely to remain residual in harvested produce when used to cultivate a short-term deciduous crop (i.e. cannabis). What these toxins do under combustion when ingested into the lungs is a completely unknown factor. However, the Material Safety Data Sheet for Paclobutrazol states that when it’s heated to decomposition it emits toxic fumes.
Daminozide was banned in the U.S. in 1989 for use on any consumable crop. Calling Alar a “potent human carcinogen” at the time, 60 Minutes ran a program that exposed the widespread use of Alar by U.S. apple growers.
So how did known carcinogens find their way back onto the market?
In each instance, these popular products were marketed to cultivators as containing organic actives (e.g. “kelp”, “rare earth elements”, “citrates”, “humatic isolates,” etc.) and sold in retail hydroponic stores throughout the U.S.
So that patients do not unwittingly become pawns in an increasingly commercial market driven by quantity and efficiency, as opposed to safety, the patient community must demand responsible cultivation methods, limiting the use of harmful pesticides, herbicides and other toxic adulterants.